Last updated on September 2018

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Brief description of study

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

Clinical Study Identifier: NCT03432533

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Wyomissing, PA United States
  Connect »